Drugs / Ga68-Dolacga Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03908957 | Feb → Aug 2019 | — | National Atomic Research Institute, Taiwan | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ga68-Dolacga Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03908957 ↗ |
| Modality | Diagnostic / imaging agent | “a PET tracer specifically targeting to surface receptors of hepatocytes” NCT03908957 ↗ |
| Route | Intravenous | “Ga68-Dolacga Injection, 3.5±0.25 mCi, single dose iv” NCT03908957 ↗ |